

11-30-2005

DEPARTMENT OF COMMERCE  
States Patent and Trademark Office

MRO 11-28-05

REC



103127135

To the Director of the U.S. Patent and Trademark Office: Please record the attached document(s) or the new address(es) below.

**1. Name of conveying party(ies)**

United Therapeutics Corporation

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

**3. Nature of conveyance/Execution Date(s):**

Execution Date(s) October 19, 2005

- ☐ Assignment ☐ Merger  
☐ Security Agreement ☐ Change of Name  
☐ Joint Research Agreement  
☐ Government Interest Assignment  
☐ Executive Order 9424, Confirmatory License  
☒ Other Discharge of Security Interest

**2. Name and address of receiving party(ies)**

Name: Altarex Medical Corp.

Internal Address: \_\_\_\_\_

Street Address: 8223 Roper Road

City: Edmonton

State: Alberta

Country: Canada

Zip: T6E 6S4

Additional name(s) & address(es) attached? ☐ Yes ☒ No

**4. Application or patent number(s):**

☐ This document is being filed together with a new application.

**A. Patent Application No.(s)**

10/754,089 09/376,604 09/994,466  
10/683,510 09/779,439 09/152,698  
10/472,167 09/871,339 09/648,663

**B. Patent No.(s)**

6,881,405 6,689,355  
6,716,966 6,241,985  
6,086,873

Additional numbers attached? ☐ Yes ☒ No

**5. Name and address to whom correspondence concerning document should be mailed:**

Name: J. Jay Haugen

Internal Address: Parlee McLaws LLP

Street Address: 1500, 10180-101 Street

City: Edmonton

State: Alberta, Canada Zip: T5J 4K1

Phone Number: (780) 423-8667

Fax Number: (780) 423-2870

Email Address: jhaugen@parlee.com

**6. Total number of applications and patents involved: 14**

**7. Total fee (37 CFR 1.21(h) & 3.41) \$ 560.00**

- ☐ Authorized to be charged by credit card  
☐ Authorized to be charged to deposit account  
☒ Enclosed  
☐ None required (government interest not affecting title)

**8. Payment Information**

a. Credit Card Last 4 Numbers \_\_\_\_\_  
Expiration Date \_\_\_\_\_

b. Deposit Account Number \_\_\_\_\_

Authorized User Name \_\_\_\_\_

**9. Signature:**

Signature

J. Jay Haugen

Name of Person Signing

Nov. 11, 2005  
Date

Total number of pages including cover sheet, attachments, and documents: 4

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to:  
Mail Stop Assignment Recordation Services, Director of the USPTO, P.O.Box 1450, Alexandria, V.A. 22313-1450

11/29/2005 ECOOPER 00000044 10754089

01 FC:8021

560.00 00

PATENT  
REEL: 017262 FRAME: 0502

## DISCHARGE OF SECURITY INTEREST

WHEREAS United Therapeutics Corporation, a Delaware corporation, is the secured party to a security agreement (the "Security Agreement") made as of April 17, 2002 with Altarex Corp., an Alberta corporation, where Altarex Corp. granted a security interest (the "Security Interest") in respect of the patents (the "Patents") and patent applications (the "Patent Applications") listed in the attached Schedule "A" to United Therapeutics Corporation;

AND WHEREAS Altarex Corp. assigned, transferred and set over its entire right, title and interest in the Patents and Patent Applications to Altarex Medical Corp., an Alberta corporation, in an Assignment of Patents and Applications instrument made as of December 31, 2003;

AND WHEREAS Altarex Corp. assigned its rights, title and interest in the Security Agreement, and delegated its obligations under the Security Agreement, to Altarex Medical Corp. in a Security Assignment Agreement made as of December 31, 2003 where the same was accepted and assumed by Altarex Medical Corp., the said assignment and assumption approved by United Therapeutics Corporation;


AND WHEREAS all of the obligations of the Security Agreement undertaken by Altarex Corp. and assumed by Altarex Medical Corp. have been fulfilled and United Therapeutics Corporation is now desirous of discharging its Security Interest in the Patents and Patent Applications.

NOW THEREFORE, IN CONSIDERATION of the foregoing, and the premises, representations and covenants contained herein, United Therapeutics Corporation hereto states as follows:

1. United Therapeutics Corporation hereby wholly discharges its Security Interest in the Patents and Patent Applications.

IN WITNESS WHEREOF, United Therapeutics has caused this Discharge of Security Interest to be executed and its seal affixed hereto this 19 day of October, 2005.

UNITED THERAPEUTICS CORPORATION

  
Name: Paul Mahon c/s  
Title: ELP + Genet Carel

Before me personally appeared Paul Mahon (name of signatory), on the date indicated below, who is known to be the person who subscribed his name above in my presence to this Discharge of Security Interest.

Dated this 19 day of October, 2005.

  
Name (Print/Type) Angela T. Ireland  
Notary Public  
Notary Public, District of Columbia  
My Commission Expires 07-31-2007

62353-45

**SCHEDULE "A"****1. CANADIAN PATENTS AND PATENT APPLICATIONS**

<b>APPLICATION NO./PATENT NO.</b>	<b>TITLE</b>	<b>FILED/ISSUED</b>
CA 2,333,221	Therapeutic compositions that produce an immune response by altering the antigen	National Entry Filed November 14, 2000.
CA 2,328,504	Immunotherapeutic composition and method for the treatment of prostate cancer	National Entry Filed November 10, 2000.
CA 2,292,912	Therapeutic composition and method of treatment	National Entry Filed December 3, 1999.
CA 2,253,602	Method and composition for reconfirming multi-epitopic antigens to initiate an immune response	National Entry Filed November 4, 1998.
CA 2,253,058	Therapeutic composition that produce an immune response	National Entry Filed November 4, 1998.

**2. UNITED STATES PATENTS AND PATENT APPLICATIONS**

<b>APPLICATION NO./PATENT NO.</b>	<b>TITLE</b>	<b>FILED/ISSUED</b>
US 6,881,405	Reagents and methods for inducing an immune response to prostate specific antigen	Issued April 19, 2005.
US 6,716,966	Therapeutic binding agents against MUC-1 antigen and methods for their use	Issued April 6, 2004.
US 6,689,355	Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells	Issued February 10, 2004.
US 6,241,985	Method and composition for reconfirming multi-epitopic antigens to initiate an immune response	Issued June 5, 2001
US 6,086,873	Therapeutic composition and method of treatment	Issued July 11, 2000
10/754,089	Therapeutic binding agents against MUC-1 antigen and methods for their use	Filed January 7, 2004
10/683,510	Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells	Filed October 10, 2003
10/472,167	Therapeutic compositions that alter the immune response	Filed September 18, 2003
09/376,604	Therapeutic compositions that alter the immune response	Filed August 18, 1999
09/779,439	Method for diagnosing efficacy of xenotypic antibody therapy	Filed February 8, 2001
09/871,339	Method and composition for reconfirming multi-epitopic antigens to initiate an immune response	Filed May 31, 2001
09/994,466	Therapeutic binding agents against MUC-1 antigen and methods for their use	Filed November 26, 2001
09/152,698	Therapeutic compositions that produce an immune response	Filed September 2, 1998
09/648,663	Therapeutic immune condition compositions and methods	Filed August 25, 2000

{E5094743.DOC;1}